Overview
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
Description
Suhexiang Pill, a traditional Chinese patent medicine, is widely used in China for acute stroke. However, there is a lack of evidence of its efficacy and safety for acute ischemic stroke in real-world setting. This registry study will recruit 1000 patients who receive Suhexiang Pill treatment after acute ischemic stroke.
Eligibility
Inclusion Criteria:
- Acute ischemic stroke within 7 days of symptom onset.
- Age ≥ 18
- Patient who has received Suhexiang Pill treatment
- Patient or legally authorized representative has signed informed consent.
Exclusion Criteria:
- Be allergic to Suhexiang Pill
- Known to be pregnant or breastfeeding.
- With conditions that render outcomes or follow-up unlikely to be assessed.